Sanofi: presents positive data on Libtayo

(CercleFinance.com) - Sanofi announces that positive results from a pivotal phase II trial of Libtayo (cemiplimab) as a monotherapy in advanced basal cell carcinoma in a late-breaking presentation at ESMO at the ESMO 2020 Congress.


"Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial," the group said.

This data will form the basis of submissions to regulatory authorities, particularly in the US and the EU. Libtayo is being jointly developed by Sanofi and Regeneron.


Copyright (c) 2020 CercleFinance.com. All rights reserved.